logo
Plus   Neg
Share
Email

Airbus Slips To Loss In Q1 With Weak Revenues Amid Covid-19

European plane maker Airbus SE (EADSF.PK,EADSY.PK) reported Wednesday that its first-quarter consolidated net loss was 481 million euros, compared to last year's profit of 40 million euros. Loss per share was 0.61 euro, compared to earnings per share of 0.05 euro a year ago.

Consolidated EBIT fell to 79 million euros from 181 million euros last year. Adjusted EBIT was 281 million euros, down from 549 million euros a year ago, mainly driven by Airbus.

Consolidated revenues decreased to 10.6 billion euros from prior year's 12.5 billion euros, reflecting the difficult market environment strongly impacted by COVID-19 situation, particularly in commercial aircraft with 40 less deliveries than a year earlier.

Net commercial aircraft orders totaled 290 with the order backlog comprising 7,650 commercial aircraft as of 31 March 2020.

Airbus Chief Executive Officer Guillaume Faury said, "We saw a solid start to the year both commercially and industrially but we are quickly seeing the impact of the COVID-19 pandemic coming through in the numbers."

Going ahead, the company said the assessment of COVID-19 implications on outlook is in progress. No new guidance issued given limited visibility

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
Follow RTT